Clearance Summary
Revaclear 500, Revaclear 400, Revaclear 300 received FDA 510(k) clearance under submission number K213639, sponsored by Baxter Healthcare Corporation. The device was reviewed via the Traditional premarket notification pathway and assigned to the Gastroenterology, Urology review panel. The statutory decision date of record is 2022-01-24.
- Submission: K213639
- Applicant / Sponsor: Baxter Healthcare Corporation
- Clearance pathway: Traditional
- Review panel: Gastroenterology, Urology
- Device class: Class II
- Regulation citation: 21 CFR 876.5860
- Decision date: 2022-01-24
Classification & Regulation
This clearance is catalogued under FDA product code KDI and 21 CFR 876.5860, within the Gastroenterology, Urology review panel as a Class II device.